1,454 Shares in The Cooper Companies, Inc. $COO Acquired by Amica Retiree Medical Trust

Amica Retiree Medical Trust acquired a new stake in The Cooper Companies, Inc. (NASDAQ:COO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,454 shares of the medical device company’s stock, valued at approximately $103,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Cerity Partners LLC raised its holdings in Cooper Companies by 6.6% during the first quarter. Cerity Partners LLC now owns 17,113 shares of the medical device company’s stock worth $1,443,000 after buying an additional 1,054 shares during the last quarter. United Services Automobile Association acquired a new position in shares of Cooper Companies during the first quarter valued at about $414,000. Ruffer LLP bought a new stake in shares of Cooper Companies during the second quarter worth about $17,624,000. Janney Montgomery Scott LLC increased its position in shares of Cooper Companies by 5.1% during the second quarter. Janney Montgomery Scott LLC now owns 97,394 shares of the medical device company’s stock worth $6,931,000 after acquiring an additional 4,761 shares in the last quarter. Finally, Asset Management One Co. Ltd. raised its holdings in shares of Cooper Companies by 3.2% in the 2nd quarter. Asset Management One Co. Ltd. now owns 88,313 shares of the medical device company’s stock worth $6,284,000 after acquiring an additional 2,746 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Insider Buying and Selling at Cooper Companies

In related news, COO Gerard H. Warner III purchased 1,450 shares of Cooper Companies stock in a transaction dated Friday, September 5th. The stock was bought at an average cost of $69.23 per share, for a total transaction of $100,383.50. Following the completion of the transaction, the chief operating officer owned 18,319 shares in the company, valued at $1,268,224.37. This trade represents a 8.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Daniel G. Mcbride acquired 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were bought at an average price of $65.04 per share, for a total transaction of $195,120.00. Following the completion of the purchase, the chief operating officer owned 63,120 shares in the company, valued at $4,105,324.80. This trade represents a 4.99% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have purchased 17,975 shares of company stock worth $1,216,346. Company insiders own 1.98% of the company’s stock.

Cooper Companies Trading Up 1.6%

Shares of COO opened at $70.10 on Friday. The Cooper Companies, Inc. has a fifty-two week low of $61.78 and a fifty-two week high of $106.63. The business has a 50-day moving average of $69.24 and a 200 day moving average of $72.64. The firm has a market cap of $13.94 billion, a P/E ratio of 34.53, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business earned $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies declared that its Board of Directors has approved a stock repurchase program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical device company to buy up to 15.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on COO shares. Weiss Ratings downgraded Cooper Companies from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. BNP Paribas raised Cooper Companies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 22nd. Wall Street Zen cut Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, July 12th. BNP Paribas Exane upgraded Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price target for the company in a report on Tuesday, July 22nd. Finally, Barclays began coverage on Cooper Companies in a research note on Monday, October 13th. They set an “overweight” rating and a $85.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.77.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.